EW - Edwards Lifesciences Corporation

NYSE - NYSE Delayed Price. Currency in USD
230.45
-0.82 (-0.35%)
At close: 4:01PM EST
Stock chart is not supported by your current browser
Previous Close231.27
Open232.14
Bid230.01 x 800
Ask229.77 x 800
Day's Range229.10 - 234.05
52 Week Range163.08 - 247.64
Volume1,595,887
Avg. Volume1,189,544
Market Cap48.065B
Beta (5Y Monthly)0.77
PE Ratio (TTM)63.28
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Edwards Lifesciences To Host Earnings Conference Call On January 30, 2020
    PR Newswire

    Edwards Lifesciences To Host Earnings Conference Call On January 30, 2020

    Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans to announce its operating results for the quarter ended December 31, 2019 after the market closes on Thursday, January 30, 2020, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

  • Edwards Lifesciences To Present At The 38th Annual J.P. Morgan Healthcare Conference
    PR Newswire

    Edwards Lifesciences To Present At The 38th Annual J.P. Morgan Healthcare Conference

    Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is scheduled to present at the J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco on Monday, January 13, 2020.

  • Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
    PR Newswire

    Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference

    Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, will discuss the company's strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance during its annual investor conference today in New York City.

  • Edwards SAPIEN 3 TAVI Receives Expanded Approval In Europe
    PR Newswire

    Edwards SAPIEN 3 TAVI Receives Expanded Approval In Europe

    IRVINE, Calif., Nov. 6, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark to expand use of the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients diagnosed with aortic stenosis who are at low risk for open-heart surgery. The Edwards SAPIEN 3 valve is the first transcatheter aortic valve implantation (TAVI) system to have this indication in Europe.

  • Edwards Lifesciences Reports Third Quarter Results
    PR Newswire

    Edwards Lifesciences Reports Third Quarter Results

    IRVINE, Calif. , Oct. 23, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today ...

  • Edwards Lifesciences To Host Earnings Conference Call On October 23, 2019
    PR Newswire

    Edwards Lifesciences To Host Earnings Conference Call On October 23, 2019

    IRVINE, Calif. , Oct. 9, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans ...

  • Edwards SAPIEN 3 TAVR Demonstrates Significant Health Status Improvements for Low-Risk Patients
    PR Newswire

    Edwards SAPIEN 3 TAVR Demonstrates Significant Health Status Improvements for Low-Risk Patients

    SAN FRANCISCO, Sept. 29, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced new data demonstrating early and sustained health status advantages for severe aortic stenosis (AS) patients at low surgical risk treated with the Edwards SAPIEN 3 valve. Study results were presented as a late-breaking clinical trial at the 31st Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, and simultaneously published online to the Journal of the American College of Cardiology. The new 1-year data, involving approximately 1,000 patients enrolled in the PARTNER 3 Trial, showed significant improvements in health status as well as overall physical and mental well-being after treatment with either transcatheter aortic valve replacement (TAVR) with the Edwards SAPIEN 3 valve or surgical aortic valve replacement.

  • GlobeNewswire

    Koa Accel Launches as New Type of Medical Device Accelerator, Embedding Expert, Invested Teams to Drive Innovations Forward, Faster, to Reduce Investor Risk

    In a move to develop medical devices faster, at a lower cost, and with a greater likelihood of a successful exit, Koa Accel today announced its launch as a next generation medical device accelerator. While mentorship and access to a modicum of business services is the cornerstone of most accelerators, Koa embeds an experienced team covering all of the critical areas of early stage medical device development. This allows Koa to fail fast or rapidly advance the venture as a de-risked startup.

  • Edwards Lifesciences To Present At The 2019 Wells Fargo Healthcare Conference
    PR Newswire

    Edwards Lifesciences To Present At The 2019 Wells Fargo Healthcare Conference

    IRVINE, Calif. , Aug. 28, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...

  • Edwards SAPIEN 3 TAVR Receives FDA Approval For Low-Risk Patients
    PR Newswire

    Edwards SAPIEN 3 TAVR Receives FDA Approval For Low-Risk Patients

    IRVINE, Calif., Aug. 16, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards SAPIEN 3 and SAPIEN 3 Ultra transcatheter heart valve systems to the treatment of severe, symptomatic aortic stenosis (AS) patients who are determined to be at low risk of open-heart surgery. "The PARTNER 3 Trial demonstrated that low-risk patients treated with the SAPIEN 3 TAVR experienced extraordinary outcomes with 1.0 percent rates of death or disabling stroke at one year, a short length of stay and 96 percent discharged to home or self-care. SAPIEN 3 is the only valve to achieve superiority over surgery based on the prespecified primary endpoint," said Martin B. Leon, M.D., director of the Center for Interventional Vascular Therapy at NewYork-Presbyterian/Columbia University Medical Center and professor of medicine at the Columbia University College of Physicians and Surgeons.

  • Edwards Lifesciences Reports Second Quarter Results
    PR Newswire

    Edwards Lifesciences Reports Second Quarter Results

    IRVINE, Calif. , July 23, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today ...

  • ACCESSWIRE

    Edwards Lifesciences Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 23, 2019 / Edwards Lifesciences Corp. (NYSE: EW ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 23, 2019 at 5:00 PM ...

  • Edwards Comments On Updated TAVR National Coverage Determination
    PR Newswire

    Edwards Comments On Updated TAVR National Coverage Determination

    "We commend CMS on its thoughtful approach toward updating the TAVR policy. Throughout the NCD process, Edwards emphasized that the priority must be ensuring timely patient access to high-quality care, so that clinicians can provide all people with heart valve disease with the therapy that is right for them.

  • Edwards Lifesciences To Present At The Goldman Sachs 40th Annual Global Healthcare Conference
    PR Newswire

    Edwards Lifesciences To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

    IRVINE, Calif. , June 4, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...

  • Edwards Lifesciences Recommends Stockholders Reject "Mini-Tender Offer" By TRC Capital Corporation
    PR Newswire

    Edwards Lifesciences Recommends Stockholders Reject "Mini-Tender Offer" By TRC Capital Corporation

    IRVINE, Calif., June 3, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received notice of an unsolicited "mini-tender offer" by TRC Capital Corporation to purchase up to 1,000,000 shares, or approximately 0.48 percent of the company's outstanding shares of common stock as of the date of the offer. Edwards does not endorse this unsolicited offer and recommends that the company's stockholders reject the offer, either by doing nothing in response or by withdrawing their shares from the offer, if they have responded. Edwards is not affiliated or associated in any way with TRC Capital, its mini-tender offer or the offer documentation.

  • Edwards Announces Milestones For Transcatheter Mitral Program
    PR Newswire

    Edwards Announces Milestones For Transcatheter Mitral Program

    Today at the EuroPCR annual course in Paris, new 6-month data from the CLASP study of the PASCAL system were presented by Konstantinos Spargias, M.D., from the Hygeia Hospital in Athens, Greece.  Patients enrolled in the CLASP study had clinically significant mitral regurgitation (MR) despite optimal medical therapy.  The results from treatment with the PASCAL system demonstrated sustained positive outcomes at six months, including 81 percent of patients with mild (1+) or none/trace MR and 98 percent with 2+ MR, with echo core lab adjudication.  Patients experienced clinically and statistically significant improvements in functional status, exercise capability and quality of life sustained at six months.

  • Edwards Lifesciences' Every Heartbeat Matters Charitable Initiative On Track to Impact 1.5 Million Underserved People By 2020
    PR Newswire

    Edwards Lifesciences' Every Heartbeat Matters Charitable Initiative On Track to Impact 1.5 Million Underserved People By 2020

    IRVINE, Calif., May 15, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the Every Heartbeat Matters signature charitable initiative is on schedule to meet its goal of impacting the global burden of heart valve disease. The initiative, which involves the education, screening and treatment of 1.5 million underserved people by 2020, is supported by grants from Edwards Lifesciences Foundation, donations of Edwards heart valve technologies, volunteer support and the dedicated work of 60 non-profit partners. "Since the Every Heartbeat Matters initiative began five years ago, we have made substantial progress in building a global community that is addressing the burden of heart valve disease for underserved people," said Amanda Fowler, executive director, Edwards Lifesciences Foundation.

  • Favorable Study Outcomes Presented On Edwards Aortic Valves With RESILIA Tissue
    PR Newswire

    Favorable Study Outcomes Presented On Edwards Aortic Valves With RESILIA Tissue

    TORONTO, May 7, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced results from the COMMENCE clinical study. The data show that Edwards' bioprosthetic surgical aortic valves featuring the company's novel RESILIA tissue platform continued to demonstrate favorable safety and hemodynamic performance through a median of four years follow-up, with no events of structural valve deterioration (SVD). The COMMENCE study enrolled 694 patients, 144 (21 percent) of which were under the age of 60 when they had surgical valve replacement.

  • Edwards Lifesciences To Webcast Annual Meeting Of Stockholders
    PR Newswire

    Edwards Lifesciences To Webcast Annual Meeting Of Stockholders

    IRVINE, Calif. , May 1, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, will ...

  • Edwards Lifesciences Reports First Quarter Results
    PR Newswire

    Edwards Lifesciences Reports First Quarter Results

    IRVINE, Calif. , April 23, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...

  • Edwards Lifesciences Completes Acquisition of CASMED
    PR Newswire

    Edwards Lifesciences Completes Acquisition of CASMED

    IRVINE, Calif., April 18, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced the completion of its acquisition of CAS Medical Systems, Inc. (CASM) (CASMED), a medical technology company dedicated to non-invasive brain and tissue oxygenation monitoring. Edwards announced in February that it had signed an agreement to acquire CASMED. Under the terms of the agreement, Edwards paid $2.45 in cash for each common share of CASMED, which equates to an equity value of approximately $100 million.

  • Edwards Lifesciences To Host Earnings Conference Call On April 23, 2019
    PR Newswire

    Edwards Lifesciences To Host Earnings Conference Call On April 23, 2019

    IRVINE, Calif. , April 9, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans ...

  • Edwards SAPIEN 3 Valve Proves Superior To Surgery In Partner 3 Trial
    PR Newswire

    Edwards SAPIEN 3 Valve Proves Superior To Surgery In Partner 3 Trial

    The trial, which compared treatment with the SAPIEN 3 valve to surgery in patients with severe symptomatic aortic stenosis (AS) at low risk of death from surgery, achieved superiority of its primary endpoint at one year. The results of the trial will be presented on Sunday as part of the late-breaking clinical trials at the American College of Cardiology's 68th Annual Scientific Session (ACC.19) in New Orleans, and have been published online in the New England Journal of Medicine.

  • Edwards Lifesciences Announces Strategic Investments
    PR Newswire

    Edwards Lifesciences Announces Strategic Investments

    IRVINE, Calif., March 11, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced two strategic transactions involving companies with structural heart disease technologies. Edwards has invested $35 million in an exclusive right to acquire Corvia Medical, Inc., the developer of the world's first transcatheter device designed to treat heart failure with preserved or mid-range ejection fraction.

  • GlobeNewswire

    Factors of Influence in 2019, Key Indicators and Opportunity within ARRIS International plc, Edwards Lifesciences, DENTSPLY SIRONA, Vail Resorts, Akers Biosciences, and DURECT — New Research Emphasizes Economic Growth

    NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.